Therapeutic Monoclonal Antibodies Markets : Market Research Report

Therapeutic Monoclonal Antibodies Markets

Published: Jun. 1, 2009 - 112 Pages

1. Introduction: 1.1 Statement of Report; 1.2 Objectives of this Report; 1.3 Scope of the Report; 1.4 Methodology; 1.5 Executive Summary
2. Introduction: The State of Therapeutic Monoclonal Antibody Technology: 2.1 State of the Pharmaceutical Industry; 2.2 Antibodies as an Alternative Pharmaceutical Agent; 2.3 Current Status of Antibody Therapeutics; 2.4 Demands of Antibody Therapeutics Development
3. Recent Technology Trends: 3.1 Classic Design of Antibodies; 3.2 Monoclonal Antibodies Therapeutics; 3.3 Synthetic Antibodies, Unique Scaffolds; 3.4 Screening and Selection of Antibodies; 3.5 Novel Antibody Modifications: Glycosylation, Pegylation, Polymer Conjugations; 3.6 Monoclonal Antibody Purification
4. Industry Challenges: 4.1 Introduction: Challenges Affecting the U.S. Therapeutic Monoclonal Antibodies Market; 4.2 Increasing Costs and Complexities of Clinical Trials; 4.3 Long-term Safety and Efficacy; 4.4 High Cost of Monoclonal Antibodies; 4.5 Restricted Government Healthcare Spending; 4.6 Intellectual Property Thicket; 4.7 Government Regulation; 4.8 Third-party Reimbursement Environment
5. Pipeline Analysis: 5.1 Overview of the Monoclonal Antibodies Pipeline; 5.2 U.S. Therapeutic Monoclonal Antibodies Market
6. Short-term Market Predictions: 6.1 Total Revenue Forecasts; 6.2 Segment Revenue Forecast; 6.3 Competitive Analysis Forecast; 6.4 Conclusions
7. Antibody Technology Companies: Profiles: 7.1 Abbott Laboratories; 7.2 Abgenix; 7.3 Ablynx; 7.4 Aeres; 7.5 Affimed Therapeutics AG; 7.6 Affitech AS; 7.7 Agensys; 7.8 Alexion Pharmaceuticals; 7.9 Amgen; 7.10 Antisoma; 7.11 ApoLife, Inc.; 7.12 Applied Molecular Evolution, Inc.; 7.13 Arana Therapeutics; 7.14 Astellas Pharma; 7.15 AstraZeneca plc; 7.16 Biogen Idec, Inc.; 7.17 BioInvent International AB; 7.18 Biosite Discovery; 7.19 Biovation Ltd.; 7.20 BioWa; 7.21 Boehringer Ingelheim; 7.22 Cambridge Antibody Technology Group; 7.23 Celltech; 7.24 Corixa; 7.25 Crucell NV; 7.26 Cytogen; 7.27 Dyax; 7.28 Eisai Co., Ltd.; 7.29 Elan Corporation; 7.30 Eli Lilly; 7.31 Elusys Therapeutics; 7.32 Enzon Pharmaceuticals; 7.33 Genentech; 7.34 Genmab A/S; 7.35 Genovac GmbH; 7.36 Genzyme Corporation; 7.37 GlaxoSmithKline plc; 7.38 GlycArt; 7.39 ILEX Oncology; 7.40 ImClone Systems; 7.41 ImmunoGen; 7.42 Immunomedics; 7.43 InNexus Biotechnology, Inc.; 7.44 Johnson & Johnson; 7.45 Lexigen; 7.46 Medarex; 7.47 MedImmune; 7.48 Merus BV; 7.49 Micromet; 7.50 Millegen; 7.51 Millennium Pharmaceuticals; 7.52 MorphoSys AG; 7.53 Novartis; 7.54 Peregrine Pharmaceuticals, Inc.; 7.55 PDL BioPharma; 7.56 Philogen; 7.57 Philotec; 7.58 Phylos; 7.59 Roche; 7.60 Sanofi-Aventis; 7.61 Scil Proteins; 7.62 Seattle Genetics; 7.63 Symphogen A/S; 7.64 Tanox; 7.65 ThromboGenics NV; 7.66 Trion Pharma; 7.67 Viventia Biotech, Inc.; 7.68 Wyeth; 7.69 Xcellerex; 7.70 Xencor, Inc.; 7.71 Xoma Ltd.; References
INDEX OF FIGURES: Figure 2.1: Worldwide Pharmaceutical Sales and R&D Expenditures, 2000-2013; Figure 2.2: International Per Capita Healthcare Spending by Country; Figure 2.3: Total Spending on Healthcare in the U.S., 1960-2007; Figure 2.4: Percentage Breakdown of U.S. Healthcare Spending, 2008; Figure 3.1: Basic Structure of the Antibody Molecule; Figure 5.1: Global Market for Protein Therapeutics, 2007-2013; Figure 6.1: Sales of the Five Leading Antibodies, 2008
INDEX OF TABLES: Table 2.1: Number of New Drug Applications to the FDA, 2000-2008; Table 2.2: New Drug Approvals from FDA, 2000-2008; Table 2.3: Percentage of GDP Healthcare Spending by Country, 2008; Table 2.4: Life Expectancy Rate by Country, 2008; Table 2.5: Development Time for Major Drugs for Top U.S. Pharmaceutical Companies; Table 2.6: Number of FDA “Black-box” Warnings, 2003-2007; Table 2.7: Collaboration and Mergers; Table 2.8: Worldwide Spending of Specialty Pharmaceuticals, 2003-2010; Table 2.9: New Drug Development from Existing Drugs; Table 3.1: Timeline of Immunological Discoveries; Table 3.2: Antibody Screening and Selection Technologies; Table 3.3: FDA-Approved Rapid HIV Antibody Screening Tests; Table 4.1: Currently Approved Therapeutic Antibodies; Table 5.1: Therapeutic Antibodies in the Development Pipeline; Table 5.2: Currently Approved Anti-Cancer Antibodies; Table 5.3: Status of Clinical Studies Involving Avastin; Table 5.4: Market for Avastin Therapeutic Antibodies, 2006-2012; Table 5.5: Rise in Herceptin Sales, 1998-2008; Table 5.6: Monoclonal Antibodies in Clinical Trials for Cardiovascular Diseases; Table 6.1: Projected World Market for Therapeutic Monoclonal Antibodies, 2008-2012; Table 6.2: Market Record and Outlook for Oncological Therapeutic Antibodies, 2006-2012; Table 6.3: Recorded and Anticipated Sales Growth for Anti-inflammatory Monoclonal Antibodies, 2006-2012; Table 7.1: Genentech’s Operating Revenue, 2004-2008; Table 7.2: Genentech’s Product Sales, 2006-2008; Table 7.3: Genentech’s Product Licensee Products; Table 7.4: Genentech’s Products in Development

Abstract

Antibodies are proteins in the immune system that help the body defend against foreign invasion, particularly from pathogens and toxins. As such, a human-engineered therapeutic monoclonal antibody (mAb) is protein derived from the immune system through recombinant DNA technology that has the ability to combine specifically with a target protein that plays a role in a disease process. With this unique ability to specifically target diseased cells while leaving healthy cells unaffected, monoclonal antibodies can serve to diagnose and treat a wide range of medical conditions. Areas such as breast cancer therapy have benefited greatly since the advent of drugs like Herceptin (trastuzumab) that interferes with the HER2/neu receptor. Indeed, the field of therapeutic monoclonal antibodies potentially has far-reaching and paradigm-shifting implications for biology, drug discovery, and medical treatment of disease. The discipline has already yielded discoveries that have been used for drug delivery and diagnostic purposes, and other exciting new therapeutic applications. This TriMark Publications report reviews the market for medical products based on emerging therapeutic monoclonal antibodies. It defines the dollar volume of sales in the U.S. and worldwide, and it analyzes the factors that influence the size and the growth of the market segments. The study goes on to discuss in detail the trends that have developed which have stimulated this market and surveys many of the companies marketing, manufacturing or developing monoclonal antibodies therapies. Monoclonal antibodies for non-therapeutic purposes--used primarily in life science and research applications--are not discussed in this review. Moreover, antibody process technology is not covered. Special effort was made to include mention of smaller companies that are or potentially could have an impact on their industry far in excess of their current size. Each company is discussed in depth with a section on the history of the company, the product line, business and marketing analysis, and a subjective commentary of the position of the company in its market.

Please note: Trimark uses a digital rights management tool to distribute their reports. The client will need to download the LockLizard DRM Software before the client will be able to access the secured PDF files. Upon ordering an electronic version, the Publisher will provide a link to download the software and the purchased

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Therapeutic Monoclonal Antibodies Markets

Table of Contents

Abstract